Novel Inhibitors of the Calcium-Activated K+ Channel KCa3.1 to Treat Non-Alcoholic Fatty Liver Disease and Liver Fibrosis

Biophysical Journal - United States
doi 10.1016/j.bpj.2018.11.1362
Full Text
Abstract

Available in full text

Categories
Biophysics
Date
Authors
Publisher

Elsevier BV

Related search

Non-Invasive Diagnosis of Fibrosis in Non-Alcoholic Fatty Liver Disease

Journal of Clinical and Experimental Hepatology
Hepatology
2012English

Portal Lymphadenopathy Predicts Non-Alcoholic Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease

PLoS ONE
Multidisciplinary
2018English

Current Modalities of Fibrosis Assessment in Non-Alcoholic Fatty Liver Disease

Journal of Clinical and Translational Hepatology
2017English

Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

PLoS ONE
Multidisciplinary
2014English

Accumulation of Duct Cells With Activated YAP Parallels Fibrosis Progression in Non-Alcoholic Fatty Liver Disease

Journal of Hepatology
Hepatology
2015English

Non-Alcoholic Fatty Liver Disease and Disease Mongering

American Journal of Medicine
Medicine
2019English

Treatment of Non-Alcoholic Fatty Liver Disease

Postgraduate Medical Journal
Medicine
2006English

Sarcopenia Is Associated With Severe Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2016English

Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis

Nutrients
NutritionFood ScienceDietetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy